Tixagevimab/AZD8895 represents a novel medicinal approach utilizing paired monoclonal proteins. Specifically, these medications operate by precisely connecting to the spike area of the SARS-CoV-2 virus, hindering its https://www.targetmol.com/compound/tixagevimab